|
| 37619245 | A Retrospective Genomic Landscape of 661 Young Adult Glioblastomas Diagnosed Using 2016 WHO Guidelines for Central Nervous System Tumors. | Oncologist | 2024 |
| 36082904 | Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors. | Oncologist | 2023 |
| 37561425 | Immunotherapy in the Treatment of Localized Genitourinary Cancers. | JAMA Oncol | 2023 |
| 37662703 | Clinical and Genomic Factors Associated with Greater Tumor Mutational Burden in Prostate Cancer. | Eur Urol Open Sci | 2023 |
| 37703595 | Genomic characterization of thymic epithelial tumors in a real-world dataset. | ESMO Open | 2023 |
| 37773629 | Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers. | Clin Cancer Res | 2023 |
| 35771716 | Method of Tissue Acquisition Affects Success of Comprehensive Genomic Profiling in Lung Cancer. | Arch Pathol Lab Med | 2023 |
| 35747993 | Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency. | Cancer Med | 2023 |
| 37217696 | Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. | Nat Rev Urol | 2023 |
| 37410975 | Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness. | JCO Precis Oncol | 2023 |
| 36977797 | Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. | Nat Rev Urol | 2023 |
| 37404765 | Genomic landscape of clinically advanced <i>KRAS</i> wild-type pancreatic ductal adenocarcinoma. | Front Oncol | 2023 |
| 37436963 | Novel SOX10 indel mutations drive schwannomas through impaired transactivation of myelination gene programs. | Neuro Oncol | 2023 |
| 37196060 | Comparative Genomic Landscape of Urothelial Carcinoma of the Bladder Among Patients of East and South Asian Genomic Ancestry. | Oncologist | 2023 |
| 36750267 | Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer. | Int J Gynecol Cancer | 2023 |
| 36650021 | Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis. | J Immunother Cancer | 2023 |
| 36443178 | Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss. | Urol Oncol | 2023 |
| 36515470 | Clear cell mesotheliomas with inactivating VHL mutations and near-haploid genomic features. | Genes Chromosomes Cancer | 2023 |
| 36690680 | Genomic landscape of 891 RET fusions detected across diverse solid tumor types. | NPJ Precis Oncol | 2023 |
| 36689222 | Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden. | JAMA Netw Open | 2023 |
| 36645099 | Genomic profiling and precision medicine in complex ameloblastoma. | Head Neck | 2023 |
| 36468266 | Novel markers in breast pathology. | Histopathology | 2023 |
| 36934870 | Cerebrospinal Venous Fistula Presenting with Cognitive Decline: Systematic Literature Review and Report of Two Cases. | World Neurosurg | 2023 |
| 36866462 | Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay. | Oncologist | 2023 |
| 36342081 | Genomic Profiling Reveals Differences in Primary Central Nervous System Lymphoma and Large B-Cell Lymphoma, With Subtyping Suggesting Sensitivity to BTK Inhibition. | Oncologist | 2023 |
| 34147313 | A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. | Urol Oncol | 2022 |
| 35705558 | Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. | Nat Commun | 2022 |
| 35704798 | Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. | JCO Precis Oncol | 2022 |
| 35820087 | Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. | JCO Precis Oncol | 2022 |
| 35598205 | Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases. | Oncologist | 2022 |
| 35598202 | Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer. | Oncologist | 2022 |
| 35749302 | Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers. | Oncologist | 2022 |
| 35357449 | Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. | JAMA Netw Open | 2022 |
| 35552752 | Variable Genomic Landscapes of Advanced Melanomas with Heavy Pigmentation. | Oncologist | 2022 |
| 36922935 | Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer. | Cancer Res Commun | 2022 |
| 36470901 | Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer. | Nat Commun | 2022 |
| 36495580 | Emerging targets in upper tract urothelial carcinomas: the TERT gene. | Can J Urol | 2022 |
| 36494601 | Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. | NPJ Precis Oncol | 2022 |
| 35970994 | Activating IGF1R hotspot non-frameshift insertions define a novel, potentially targetable molecular subtype of adenoid cystic carcinoma. | Mod Pathol | 2022 |
| 36069892 | Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma Specimens. | Oncologist | 2022 |
| 35962750 | Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization. | Oncologist | 2022 |
| 36302564 | Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types. | J Immunother Cancer | 2022 |
| 36028784 | PD-L1 protein expression in relation to recurrence score values in early-stage ERâ¿¿+â¿¿breast cancer. | Breast Cancer Res Treat | 2022 |
| 36088616 | SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer. | Clin Cancer Res | 2022 |
| 35881043 | Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study. | Oncologist | 2022 |
| 36190522 | Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial. | Clin Cancer Res | 2022 |
| 35876752 | Comprehensive Molecular Profiling of Oncocytic Salivary Gland Malignancies. | Appl Immunohistochem Mol Morphol | 2022 |
| 35102630 | NTRK gene fusions are detected in both secretory and non-secretory breast cancers. | Pathol Int | 2022 |
| 35283158 | The Paradoxical Role of Body Mass Index in Patients with Muscle-invasive Bladder Cancer Receiving Neoadjuvant Immunotherapy. | Eur Urol Oncol | 2022 |
| 35034043 | HPV51-associated Leiomyosarcoma: A Novel Class of TP53/RB1-Wildtype Tumor With Predilection for the Female Lower Reproductive Tract. | Am J Surg Pathol | 2022 |